Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines.

Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of generic availability in the United States, underscoring the Company's commitment to execution excellence and supply reliability. Sugammadex Injection (100mg/ml) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.

The Bridion® brand (100mg/ml) had U.S. sales of approximately $1.6 billion for the latest 12-month period ended May 2026, according to IQVIA National Sales Perspectives data.